Effects of hesperidin on the progression of hypercholesterolemia and fatty liver induced by high-cholesterol diet in rats

Journal of Pharmacological Sciences

Volumn 117, Issue 3, 2011, Pages 129-138

  Wang, Xinhui ^a   Hasegawa, Junichi ^a   Kitamura, Yoshiyuki ^a   Wang, Zhongzhi ^a   Matsuda, Akiko ^a   Shinoda, Waka ^a   Miura, Norimasa ^a   Kimura, Koji ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Fatty liver; Hesperidin; Hypercholesterolemia; Lipid metabolism related gene

Indexed keywords

CAMPESTEROL; CHOLESTEROL; FATTY ACID BINDING PROTEIN; HESPERIDIN; LATHOSTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; RETINOL BINDING PROTEIN 4; SITOSTEROL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; FATTY LIVER; GAS CHROMATOGRAPHY; GENE EXPRESSION; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; LIVER WEIGHT; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; TISSUE LEVEL; WISTAR RAT;

EID: 81455149976     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11097FP     Document Type: Article

References (64)

1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation. 2002;106:3143-3421.
2. Loguercio C, De Simone T, D'Auria MV, De Sio I, Federico A, Tuccillo C, et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the liver. Dig Liver Dis. 2004;36:398-405. (Pubitemid 41122210)
3. Loguercio C, De Girolamo V, De Sio I, Tuccillo C, Ascione A, Baldi F, et al. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects. J Hepatol. 2001;35:568-574. (Pubitemid 33078265)
4. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438. (Pubitemid 10057164)
5. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99-S112.
6. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929-1934.
7. Hamaguchi M, Kojima T, Takeda N, Nagata C, Takeda J, Sarui H, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007;13:1579-1584. (Pubitemid 46672668)
8. Arslan U, Turkoglu S, Balcioglu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis. 2007;18:433-436. (Pubitemid 47262963)
9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
10. Tsutsumi C, Okuno M, Tannous L, Piatedosi R, Allan M, Goodman DS, et al. Retinoids and retinoid-binding protein expression in rat adipocytes. J Biol Chem. 1992;267:1805-1810.
11. Margareto J, Gomez-Ambrosi J, Marti A, Martinez JA. Time-dependent effects of a high energy-yielding diet on the regulation of specific white adipose tissue genes. Biochem Biophys Res Commun. 2001;283:6-11. (Pubitemid 32912528)
12. Kushiro M, Takahashi Y, Ide T. Modulation of cutaneous fatty acid-binding protein mRNA expression in rat adipose tissues by hereditary obesity and dietary fats. J Oleo Sci. 2007;56:533-541.
13. Chmurzyñska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 2006;47:39-48. (Pubitemid 43232158)
14. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40:781-786.
15. Donnelly KL, Smith CL, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005;115:1343-1351. (Pubitemid 40629054)
16. Gorinstein S, Caspi A, Libman I, Katrich E, Lerner HT, Trakhtenberg S. Preventive effects of diets supplemented with sweetie fruits in hypercholesterolemic patients suffering from coronary artery disease. Preventive Med. 2004;38:841-847. (Pubitemid 38757536)
17. Roza JM, Xian-Liu Z, Guthrie N. Effect of citrus flavonoids and tocotrienols on serum cholesterol levels in hypercholesterolemic subjects. Altern Ther Health Med. 2007;13:44-48. (Pubitemid 351299592)
18. Miyake Y, Yamamoto K, Tsujihara N, Osawa T. Protective effects of lemon flavonoids on oxidative stress in diabetic rats. Lipids. 1998;33:689-695. (Pubitemid 28328798)
19. Morand C, Dubray C, Milenkovic D, Lioger D, Martin JF, Scalbert A, et al. Hesperidin contributes to the vascular protective effects of orange juice: a randomized crossover study in healthy volunteers. Am J Clin Nutr. 2011;93:73-80.
20. Chiba H, Uehara M, Wu J, Wang X, Masuyama R, Suzuki K, et al. Hesperidin, a citrus flavonoid, inhibits bone loss and decreases serum and hepatic lipids in ovariectomized mice. J Nutr. 2003;133:1892-1897. (Pubitemid 36666531)
21. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-α formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther. 2005;313:502-509. (Pubitemid 40604148)
22. Murata Y, Kojima N, Kawashima S. Functions of a chitosan-orotic acid salt in the gastrointestinal tract. Biol Pharm Bull. 2003;26:687-690. (Pubitemid 39663564)
23. Koopman R, Schaart G, Hesselink MK. Optimisation of oil red O staining permits combination with immunofluorescence and automated quantification of lipids. Histochem Cell Biol. 2001;116:63-68. (Pubitemid 32695819)
24. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 2001;25:402-408. (Pubitemid 34164012)
25. Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem. 2000;285:194-204.
26. Nobuo Y, Yoshio O, Azharul I, Hiroko M, Masahiro Y, Masachika K, et al. Utility of 19-hydroxycholesterol as an internal standard compound for the quantitative determination of sterols using capillary gas chromatograph. Yonago Acta Medica. 2002;45:27-33.
27. Weihrauch JL, Gardner JM. Sterol content of foods or plant origin. J Am Diet Assoc. 1978;73:39-47.
28. Miettinen TA, Tilvis RS, Kesaniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990;131:20-31. (Pubitemid 20014696)
29. Kempen HJM, Glatz JFC, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988;29:1149-1155.
30. Castelli WP. Incidence of coronary heart disease and lipoprotein cholesterol levels. JAMA. 1986;256:2835-2838. (Pubitemid 17178361)
31. Sun L, Lu SZ. Association between non-alcoholic fatty liver disease and coronary artery disease severity. Chin Med J. 2011;124:867-872.
32. Rader DJ. High-density lipoproteins and atherosclerosis. Am J Cardiol. 2002;90:62-70.
33. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50 Suppl: S189-S194.
34. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366:1849-1861.
35. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.
36. Soprano DR, Soprano KJ, Goodman DS. Retinol-binding protein messenger RNA levels in the liver and in extrahepatic tissues of the rat. J Lipid Res. 1986;27:166-171. (Pubitemid 16049114)
37. Tsutsumi C, Okuno M, Tannous L, Piatedosi R, Allan M, Goodman DS, et al. Retinoids and retinoid-binding protein expression in rat adipocytes. J Biol Chem. 1992;267:1805-1810.
38. Kushiro M, Takahashi Y, Ide T. [The relationship between obesity and discovered lipid metabolism related genes with expression levels changes due to a high fat diet]. http://www.nfri.affrc.go.jp/research/seika/seikah15/pdf/ h15p12.pdf. Shokuhin Kenkyu Seika Joho. no. 16. 2004. p. 12-13. (in Japanese)
39. Desvergne B. RXR: from partnership to leadership in metabolic regulations. Vitam Horm. 2007;75:1-32.
40. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? J Hepatol. 2006;44:253-261. (Pubitemid 43071224)
41. Stefan N, Hennige AM, Staiger H, Machann J, Schick F, Schleicher E, et al. High circulating retinol-binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans. Diabetes Care. 2007;30:1173-1178. (Pubitemid 46684644)
42. Takebayashi K, Suetsugu M, Matsumoto S, Aso Y, Inukai T. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J. 2009;102:361-368.
43. Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther. 2004;26:1368-1387. (Pubitemid 39572152)
44. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-insensitivity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556-1565.
45. Binas B, Danneberg H, Mcwhir J, Mullins L, Clark AJ. Requirement for heart-type fatty acid binding protein in cardiac fatty acid utilization. FASEB J. 1999;13:805-812. (Pubitemid 29220693)
46. Marti A, Vaquerizo J, Zulet MA, Moreno-Aliaga MJ, Martinez JA. Down-regulation of heart HFABP and UCP2 gene expression in diet-induced (cafeteria) obese rats. J Physiol Biochem. 2002;58:69-74. (Pubitemid 35230081)
47. Matsuda A, Wang Z, Takahashi S, Tokuda T, Miura N, Hasegawa J. Upregulation of mRNA of retinoid binding protein and fatty acid binding protein by cholesterol enriches-diet and effect of ginger on lipid metabolism. Life Sci. 2009;84:903-907.
48. Zimmerman AW, Veerkamp JH. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci. 2002;59:1096-1116.
49. Kushiro M, Takahashi Y, Ide T. Modulation of cutaneous fatty acid-binding protein m RNA expression in rat adipose tissues by hereditary obesity and dietary fats. J Oleo Sci. 2007;56:533-541.
50. Brown AJ. Atherosclerosis: cell biology and lipoproteins: cholesterol absorption inhibitors: gateway therapy for hypercholesterolemia. Curr Opin Lipidol. 2002;13:701-703. (Pubitemid 36009211)
51. Kempen HJ, Glatz JF, Gevers Leuven JA, van der Voort HA, Katan MB. Serum lathosterol concentration is an indicator of whole-body cholesterol synthesis in humans. J Lipid Res. 1988;29:1149-1155.
52. Simonen P, Kotronen A, Hallikianen M, Sevastianova K, Makkonen J, Hakkarainen A, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol. 2011;54:153-159.
53. Silbernagel G, Fauler G, Benner W, Landl EM, Hoffmann MM, Winkelmann BR, et al. The relationship of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. J Lipid Res. 2009;50:334-341.
54. Noto D, Cefalu AB, Barraco G, Martino E, Fayer F, Mina M, et al. Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. Pediatric Res. 2010;67:200-204.
55. Suckling KE, Stange EF. Role of acyl-CoA, cholesterol acyl-transferase in cellular cholesterol metabolism. J Lipid Res. 1985;26:647-671. (Pubitemid 15248938)
56. Jung UJ, Lee M-K, Park YB, Kang MA, Choi M-S. Effect of citrus flavonoids on lipid metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Intl J Biochem Cell Biol. 2006;38:1134-1145.
57. Bok S-H, Lee S-H, Park Y-B, Bae K-H, Son K-H, Jeong T-S, et al. Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methylglutaryl-CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids. J Nutr. 1999;129:1182-1185. (Pubitemid 29250168)
58. Wilcox LJ, Borradaile NM, de Dreu LE, Huff MW. Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP. J Lipid Res. 2001;42:725-734. (Pubitemid 32507172)
59. Morin B, Nichols LA, Zalasky KM, Davis JW, Manthey JA, Holland LJ. The citrus flavonoids hesperetin and nobiletin differentially regulate low density lipoprotein receptor gene transcription in HepG2 liver cells. J Nutr. 2008;138:1274-1281. (Pubitemid 351930989)
60. Nichols LA, Jackson DE, Manthey JA, Shukla SD, Holland LJ. Citrus flavonoids repress the mRNA for stearoyl-CoA desaturase, a key enzyme in lipid synthesis and obesity control, in rat primary hepatocytes. Lipid Health Dis. 2011;10:36.
61. Rizza S, Muniyappa R, Lantorno M, Kim J, Chen H, Pullikotil P, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab. 2011;96:782-792.
62. Miwa Y, Yamada M, Sunayama T, Mitsuzumi H, Tsuzaki Y, Chaen H, et al. Effects of glucosyl hesperidin on serum lipids in hyperlipidemic subjects: preferential reduction in elevated serum triglyceride level. J Nutr Sci Vitaminol (Tokyo). 2004;50:211-218. (Pubitemid 39045124)
63. Kurowska EM, Spence JD, Jordan J, Wetmore S, Freeman DJ, Piché LA, et al. HDL-cholesterol-raising effect of orange juice in subjects with hypercholesterolemia. Am J Clin Nutr. 2000;72:1095-1100.
64. Demonty I, Lin Y, Zebregs YE, Vermeer MA, van der Knaap HC, Jäkel M, et al. The citrus flavonoids hesperidin and naringin do not affect serum cholesterol in moderately hypercholesterolemic men and women. J Nutr. 2010;140:1615-1620.